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Abstract
Background: Although beneficial in clinical practice, the INtubate-SURfactant-Extubate (IN-SUR-E) method is not
successful in all preterm neonates with respiratory distress syndrome, with a reported failure rate ranging from 19 to 69 %.
One of the possible mechanisms responsible for the unsuccessful IN-SUR-E method, requiring subsequent re-intubation
and mechanical ventilation, is the inability of the preterm lung to achieve and maintain an “optimal” functional residual
capacity. The importance of lung recruitment before surfactant administration has been demonstrated in animal studies
showing that recruitment leads to a more homogeneous surfactant distribution within the lungs. Therefore, the aim of
this study is to compare the application of a recruitment maneuver using the high-frequency oscillatory ventilation (HFOV)
modality just before the surfactant administration followed by rapid extubation (INtubate-RECruit-SURfactant-Extubate:
IN-REC-SUR-E) with IN-SUR-E alone in spontaneously breathing preterm infants requiring nasal continuous positive airway
pressure (nCPAP) as initial respiratory support and reaching pre-defined CPAP failure criteria.
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Methods/design: In this study, 206 spontaneously breathing infants born at 24+0–27+6 weeks’ gestation and failing
nCPAP during the first 24 h of life, will be randomized to receive an HFOV recruitment maneuver (IN-REC-SUR-E) or
no recruitment maneuver (IN-SUR-E) just prior to surfactant administration followed by prompt extubation. The primary
outcome is the need for mechanical ventilation within the first 3 days of life. Infants in both groups will be considered to
have reached the primary outcome when they are not extubated within 30 min after surfactant administration or when
they meet the nCPAP failure criteria after extubation.
Discussion: From all available data no definitive evidence exists about a positive effect of recruitment before surfactant
instillation, but a rationale exists for testing the following hypothesis: a lung recruitment maneuver performed with a
step-by-step Continuous Distending Pressure increase during High-Frequency Oscillatory Ventilation (and not with a
sustained inflation) could have a positive effects in terms of improved surfactant distribution and consequent its major
efficacy in preterm newborns with respiratory distress syndrome. This represents our challenge.
Trial registration: ClinicalTrials.gov identifier: NCT02482766. Registered on 1 June 2015.
Keywords: Preterm infants, Lung recruitment, HFOV, INSURE
Background
The pathogenesis of bronchopulmonary dysplasia (BPD)
in preterm infants is multifactorial, but the role of
ventilator-induced lung injury (VILI) is very important [1].
Although the respiratory support of preterm infants with
respiratory distress syndrome (RDS) has improved and
new modes of mechanical ventilation have been devel-
oped, the incidence of BPD has remained unchanged.
Avoiding invasive mechanical ventilation by starting non-
invasive respiratory support, such as continuous positive
airway pressure (CPAP), in the delivery room is consid-
ered an important first step in reducing VILI and BPD. In
case invasive mechanical ventilation is necessary, the re-
cruitment of collapsed alveoli, thereby creating an optimal
functional residual capacity (FRC) and limiting exposure
to large tidal volumes and repetitive “opening and closing”
of the unstable alveoli, may be the most effective way to
reduce the risk of VILI and subsequent BPD.
The findings from the COIN [2], SUPPORT [3], and
VON DRM [4] trials – comparing Early CPAP versus
standard care (intubate, surfactant, mechanical ventila-
tion) – are remarkably consistent. No single trial was able
to demonstrate a statistically significant difference in the
risk of death or BPD when infants were managed initially
with CPAP compared to mechanical ventilation. From the
results of these three studies, it is clear that initial
stabilization on CPAP, and provision of rescue surfactant
only when necessary, is at least as beneficial, and quite
possibly preferred, over the standard therapy of intubation
of all infants at risk in the delivery room and needing sub-
sequent support with mechanical ventilation. The Italian
Neonatal Network report of 2012 showed that an initial
nasal continuous positive airway pressure (nCPAP) ap-
proach was used in approximately 60 % of cases, while
Dargaville et al. [5] have reported that 50 % of newborns
with gestational age (GA) 25–28 weeks were initially man-
aged with nCPAP, substantially lower than the 65–90 %
reported in other studies [6, 7]. The percentage of CPAP
failure in the newborns of 25–28 weeks’ gestation is 45 %
in the Australian experience [5], higher than that reported
by Ammari et al. (25 %) [6] and similar to that reported by
De Jaegere et al. (50 %) [7] and in the COIN trial (46 %)
[2]. Therefore, the optimal respiratory care of newborn in-
fants with RDS may involve yet another choice.
As a potential alternative, the IN-SUR-E (INtubate-
SURfactant-Extubate) approach [8] is very attractive.
Recently, several studies have investigated the efficacy of
combining non-invasive ventilation and surfactant,
administered by transient intubation (IN-SUR-E). The
findings from the CURPAP [9] and VON DRM [4] trials
– comparing Early IN-SUR-E versus Early CPAP as ini-
tial stabilization – showed no differences in mortality,
BPD or any other outcome. In the VON DRM trial 51 %
of infants in the IN-SUR-E group were later intubated.
Although beneficial in clinical practice, the IN-SUR-E
method cannot be universally applied to all preterm neo-
nates with RDS with a reported failure rate ranging from
19 to 69 % [10, 11]. The reported risk factors predicting
a failure of IN-SUR-E are low birth weight, low gesta-
tional age, the severity of initial respiratory disease, and
a low hemoglobin concentration prior to surfactant
administration [10, 12, 13]. No randomized controlled
trials have directly evaluated the efficacy of IN-SUR-E in
extremely preterm neonates (above 28 weeks’ gestation)
[8]. Nevertheless, the data of the “Sustained Lung Infla-
tion (SLI) study” [14] recently conducted on infants with
GA 25+0–28+6 weeks showed that nCPAP failure and the
need for MV at 72 h of life was 53 % in the SLI group
and 65 % in the control group (only nCPAP). In this
study surfactant was preferably administered with the
IN-SUR-E approach at a FiO2 threshold of 0.40, suggest-
ing that at least 50 % of 25–28 weeks’ gestation infants
need mechanical ventilation in the first 72 h of life, despite
receiving a SLI maneuver and IN-SUR-E treatment for
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CPAP failure. One of the possible mechanisms responsible
for the unsuccessful IN-SUR-E, requiring subsequent re-
intubation and mechanical ventilation is the inability of
the preterm lung with RDS to achieve and maintain an
“optimal” FRC. Prophylactic or early rescue surfactant
administration before alveolar recruitment probably
results in an uneven surfactant distribution to already-
open alveoli, thus resulting in poor clinical response to the
first surfactant dose. The immediate positive effects of
surfactant on oxygenation are primarily attributable to
the stabilization of already-open alveoli, and not due
to recruitment of collapsed ones. The importance of
lung recruitment before surfactant administration has
been demonstrated by Krause and colleagues [15] in a
piglet model of lung injury where a volume recruit-
ment maneuver by means of moderately increased
tidal volumes or increased PEEP or both, improved
gas exchange and lung function owing to more
homogeneous surfactant distribution within the lungs.
Volume recruitment was proven by improved compli-
ance and increased FRC in all the intervention
groups. We, therefore, seek to compare the applica-
tion of a recruitment maneuver (in HFOV modality)
just before the surfactant administration, followed by
rapid extubation (INtubate-RECruit-SURfactant-Extu-
bate: IN-REC-SUR-E) with IN-SUR-E alone in spon-
taneously breathing preterm infants requiring nCPAP
as initial respiratory support and reaching pre-defined
CPAP failure criteria, for evaluating its effectiveness
in decreasing the need of MV and improving respira-
tory outcome.
Trial hypothesis
The primary hypothesis of this study is that there will be
a reduction in the need of mechanical ventilation in the
first 72 h of life (excluding the transient tracheal intub-
ation performed for surfactant administration and the
mechanical ventilation administered for lung recruit-
ment) in spontaneously breathing infants born at 24+0–
27+6 weeks’ gestation and failing nCPAP during the first
24 h of life who received an HFOV recruitment maneu-
ver (IN-REC-SUR-E) compared to those receiving no
recruitment maneuver (IN-SUR-E) just prior to surfac-
tant administration followed by prompt extubation.
Methods/design
Study design
This will be an unblinded multi-center randomized trial
of IN-REC-SUR-E versus IN-SUR-E in infants born at
24+0–27+6 weeks’ gestation.
Participating centres
The following Italian centres are actively recruiting for
the trial:
Policlinico Gemelli, Rome; S. Pietro Fatebenefratelli,
Rome; Fatebenefratelli-Isola Tiberina, Rome; Policlinico
Umberto I, Rome; Bel Colle Hospital, Viterbo; Fondazione
Poliambulanza, Brescia; Fondazione MBBM – Ospedale San
Gerardo, Monza; Niguarda Hospital, Milan; Fondazione
IRCCS Cà Granda Ospedale Maggiore Policlinico, Univer-
sity Milan, Milan; AO Carlo Poma, Mantova; SS Antonio e
Biagio e Cesare Arrigo Hospital, Alessandria; Maggiore Hos-
pital, Novara; AOU Ospedali Riuniti, Foggia; AO Vito Fazzi,
Lecce; Villa Betania, Naples; Careggi University, Florence;
Pineta Grande, Castelvolturno; AO S. Anna-S. Sebastiano,
Caserta; Maggiore Hospital, Bologna; AOU, Ferrara; AO,
Cosenza; Di Venere Hospital, Bari; AO G. Rummo, Bene-
vento; Panico Hospital, Tricase; Bolzano Hospital; Arcispe-
dale Santa Maria Nuova, Reggio Emilia; Salesi Hospital,
Ancona; Barone Romeo Hospital, Patti; AOU Parma; AOU
Policlinico Vittorio Emanuele-Gaspare Rodolico, Catania;
Messina University; Arnas Civico Hospital, Palermo; San
Bortolo Hospital, Vicenza; AOU Policlinico, Modena; San
Salvatore Hospital, L’Aquila; AO Bianchi-Melacrino-Morelli,
Reggio Calabria; AO Cà Foncello, Treviso.
Based on the last Italian survey on behalf of the Neonatal
Pneumology Study Group (not yet published), most of the
participant centers use HFOV “open lung strategy” as a first
line ventilatory management of preterm infants with RDS.
The centers which do not use this approach (but use
HFOV as a “rescue” therapy), have experienced the “open
lung” HFOV maneuver before starting the study, after an
on-site training.
We estimate that the participating centres will have a
minimum of 5 and a maximum of 20 eligible patients
during the study period with 80 % assumed consent rate.
Inclusion criteria
Infants satisfying the following inclusion criteria will be
eligible to participate:
(1) In-born at 24+0–27+6
(2) spontaneously breathing at birth but requiring
respiratory support (CPAP or O2) at 5 min of life
(3) Parental consent has been obtained
(4) Failing nCPAP during the first 24 h of life
Exclusion criteria
(1) Severe birth asphyxia or a 5-min Apgar score <3
(2) Endotracheal intubation in the delivery room for
resuscitation or insufficient respiratory drive
according to AAP guidelines [16].
(3) Prolonged premature rupture of membranes
(PROM) for more than 3 weeks
(4) Presence of major congenital malformations
(5) Hydrops fetalis
(6) Inherited disorders of metabolism
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Sample size
We hypothesized that a recruitment maneuver (in HFOV
modality) before surfactant administration might decrease
of the need of subsequent mechanical ventilation during
the first 72 h of life from 50 % [2, 5, 7] to 30 %. We calcu-
lated that 103 newborns must be enrolled in each group
to detect this difference as statistically significant with
80 % power at the 0.05 alpha level using the two-sided
Pearson’s chi-square test.
Randomisation
Infants will be allocated to one of the two treatment
groups in a 1:1 ratio according to the minimization
method, using an interactive web-based electronic sys-
tem. Randomization will be stratified by center and ges-
tational age (24+0–25+6 weeks or 26+0–27+6 weeks). A
monthly accrual report about the study will be sent to
the participating centers.
Blinding
The study will not be blinded, and the staff performing
the study also will take subsequent care of the infants.
Management in the delivery room
Positive pressure with a neonatal mask and a T-piece
system (Neopuff Infant Resuscitator ®, Fisher and Paykel,
Auckland, New Zealand) will be used to stabilize the
newborns after birth. All the neonates will receive one
(or two) SLI maneuver(s) (25 cmH2O for 10–15 s)
[14] and will be transferred to the NICU on nCPAP
(6 cmH2O). If necessary, infants will start mechanical
ventilation in agreement with the American Academy
of Pediatrics’ guidelines on neonatal resuscitation [16].
In this latter case the babies will be excluded from
the study (see Exclusion criteria section, page 4).
CPAP failure criteria
In the NICU, nCPAP will be given through nasal prongs/
mask using the standard method of the single centre
(ventilator, flow-dependent system) with an initial
pressure of 6 to 7 cmH2O, in all infants. CPAP failure
is defined if they met any of the following criteria:
FiO2 ≥ 0.30 on nCPAP [17] to maintain a SpO2 of
87–94 % [18] for at least 30 min unless rapid clinical
deterioration has occurred; respiratory acidosis de-
fined as pCO2 > 65 mmHg (8.5 kPa) and pH <7.20 on
an arterial or capillary blood gas sample; apnea de-
fined as more than four episodes of apnea per hour
or more than two episodes of apnea per hour when
ventilation with bag and mask will be required.
HFOV recruitment maneuver
Infants in the IN-REC-SUR-E group will undergo the
following approach: after intubation, HFOV will be
delivered with the ventilator available in each NICU.
The following initial ventilator setting will be advocated:
continuous distending pressure (CDP): 8 cmH2O;
frequency: 10–15 Hz; ΔP: 15 cmH2O or amplitude 30 %
eventually increased – chest to be “visibly vibrating”; I:E
1:2. ΔP (or amplitude) first and/or frequency will subse-
quently be adjusted to achieve a tidal volume (VT) of
1.5–2 ml/kg and/or to maintain the transcutaneous
partial carbon dioxide pressure (TcPCO2) between 40
and 60 mmHg (5.3 and 8.0 kPa). The infants will be
subjected to an open lung ventilation strategy aiming to
recruit and stabilize the majority of collapsed alveoli/
sacculi, using oxygenation as an indirect parameter for
lung volume. Optimal recruitment is defined as adequate
oxygenation using a fraction of inspired oxygen (FiO2) of
0.25 or less. Starting at 8 cmH2O, the CDP will be in-
creased stepwise (2 cmH2O every 2–3 min) as long as
pulse oximetry (SpO2) improves. The FiO2 will be re-
duced stepwise, keeping SpO2 within the target range
(87–94 %). The recruitment procedure will be stopped if
oxygenation no longer improves or if the FiO2 is equal
to or less than 0.25. The corresponding CDP will be
called the opening pressure (CDPO). Next, the CDP will
be reduced stepwise (1–2 cmH2O every 2–3 min) until
the SpO2 deteriorates (by at least 2–3 points). The cor-
responding CDP will be called the closing pressure
(CDPC). After a second recruitment maneuver at CDPO
for 2 min, the optimal CDP (CDPOPT) will be set 2
cmH2O above the CDPC for at least 3 min [19]. A chest
radiograph at this point is advised.
Surfactant treatment
Infants in the IN-REC-SUR-E arm will undergo the fol-
lowing approach: as soon as possible after the recruitment
maneuver (at CDPOPT) a dose of poractant alfa (Curosurf
(Chiesi Farmaceutici, Parma, Italy)) of 200 mg/kg will be
administered via a closed administration system in one to
two aliquots (1–2 min). The tube position will be
confirmed by auscultation. A temporary reduction of
frequency may be necessary to increase the VT up to
2.5 ml/kg for improving the surfactant spreading.
Infants in the IN-SUR-E arm will undergo the fol-
lowing approach: after intubation, a dose of poractant
alfa (Curosurf (Chiesi Farmaceutici, Parma, Italy)) of
200 mg/kg will be administered via a closed adminis-
tration system in one to two aliquots (1–2 min). The
tube position will be confirmed by auscultation. Dur-
ing surfactant administration, infants will be manually
ventilated to facilitate surfactant distribution. If neces-
sary, mechanical ventilation with a peak inspiratory
pressure (PIP) of 20–22 cmH2O, a PEEP of 5–6
cmH2O and a respiratory rate of 30–40 breaths/min
will be subsequently started to achieve a VT of 4–
6 ml/kg and/or to maintain the transcutaneous partial
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carbon dioxide pressure (TcPCO2) between 40 and
60 mmHg (5.3 and 8.0 kPa).
After surfactant administration, the babies of both groups
will be extubated within 30 min (if satisfactory respiratory
drive is present) and will receive nCPAP (6–8 cmH2O)
[20]. In case of insufficient respiratory drive, CDP and/or
ΔP (in the babies of IN-REC-SUR-E arm) or PIP (in the
IN-SUR-E arm) will be reduced until spontaneous respira-
tory activity is restored, to maintain the transcutaneous par-
tial carbon dioxide pressure (TcPCO2) between 40 and
60 mmHg (5.3 and 8.0 kPa). Maintaining a FiO2 < 0.30 to
obtain SpO2 values in the desired range (87–94 %) will
drive the eventual reduction in the level of CPAP in the fol-
lowing days. The decision as to whether to begin bi-level
nCPAP (BiPAP) or nasal intermittent MV (N-IMV) to
prevent the need for re-intubation in infants of both
groups will be up to the neonatologist on duty, and will be
considered in the final analysis.
Infants of both groups can receive a subsequent dose of
surfactant (100 mg/kg of poractant alfa) using the same
method (IN-SUR-E or IN-REC-SUR-E) if they meet the
CPAP failure criteria again during the following 12 to 24 h.
Caffeine
A loading dose of caffeine citrate (20 mg/kg) will be
given immediately after admission to the NICU, followed
by a daily maintenance dose of 5–10 mg/kg.
Analgesia-sedation
All neonates will receive pre-intubation medications to
provide adequate analgesia and sedation while preserving
spontaneous respiratory activity during the procedure of
surfactant administration, according to the local protocols
involving the use of opioids (fentanyl or remifentanil).
Primary outcome measure
The primary outcome is the need for mechanical ventila-
tion within the first 3 days of life and, therefore, we con-
sider IN-REC-SUR-E or IN-SUR-E a success if mechanical
ventilation is not required and a failure if the infant needs
mechanical ventilation in the first 72 h. Infants in both
groups will be considered to have reached the primary
outcome also when they are not extubated within 30 min
after surfactant administration or when they meet the
nCPAP failure criteria after extubation.
Secondary outcome measures
(1) Duration (days) of nCPAP, need and duration of
bi-level NCPAP (BiPAP) and nasal intermittent MV
(N-IMV)
(2) Need and duration (days) of conventional mechanical
ventilation (synchronized intermittent mandatory
ventilation (SIMV), synchronized intermittent
positive pressure ventilation (SIPPV), pressure
support ventilation (PSV) with or without volume
guarantee (VG)) or high-frequency oscillatory
ventilation (HFOV) with or without VG
(3) Duration (days) of oxygen therapy and highest FiO2
level of oxygen concentration
(4) Duration of hospitalization
(5) Number of doses of surfactant during hospitalization
(6) Occurrence of mild, moderate, and severe
bronchopulmonary dysplasia (BPD) during
hospitalization. The severity of BPD is categorized
according to the consensus definition [21]: treatment
with oxygen >21 % for at least 28 days, plus: mild
BPD: breathing room air at 36 weeks post menstrual
age (PMA) or discharge, whichever comes first;
moderate BPD: need for more than 30 % oxygen at
36 weeks PMA or discharge, whichever comes first;
severe BPD: need for at least 30 % oxygen and/or
positive pressure (PPV or nCPAP) at 36 weeks PMA
or discharge, whichever comes first
(7) Time of being without any respiratory support
Other collected data
The following data will be recorded for each infant: ges-
tational age (GA), birth weight (BW), sex, Apgar score at
5 min, antenatal steroid treatment, prolonged PROM of
more than 18 h, diagnosis of histological and/or clinical
chorioamnionitis, type of delivery, clinical risk index for
babies (CRIB) II score [22], occurrence of air leaks,
pulmonary hemorrhage, patent ductus arteriosus (PDA)
and need for surgical closure, timing of surfactant ad-
ministration, grades 3–4 intraventricular hemorrhage
(IVH) [23], periventricular leukomalacia (PVL) [24],
higher than grade 2 retinopathy of prematurity (ROP)
[25], necrotizing enterocolitis (NEC) [26], sepsis defined
as a positive blood culture or suggestive clinical and la-
boratory findings leading to treatment with antibiotics
for at least 7 days despite the absence of a positive blood
culture, length of stay in the NICU, use of systemic post-
natal steroids, and mortality. The discharge from NICU
will be performed when infants will not need respiratory
assistance other than using oxygen therapy and central
venous catheter insertion.
Data collection
All collected data can be obtained from the clinical
records. They will be reported in electronic data sheets
designed for this study. Data will be entered by the local
principal investigator on a web-based electronic case
record form. Access to the form will be password-
protected and participants will be identified by trial
number only. Clinical information will be collected at
the following times:
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1) At trial entry: information on eligibility; background
information and randomization
2) Following randomisation: all data above listed in
“Primary outcome measure,” “Secondary outcome
measure,” and “Other collected data” sections
Further information will be collected on expected
serious adverse events.
In terms of the PICOT format, our study can be de-
scribed as follows: P: preterm infants of 24-27 weeks fail-
ing nCPAP during the first 24 h of life; I: surfactant
administered during HFOV with optimal lung volume
strategy; C: surfactant administration via INSURE method
using conventional positive pressure ventilation; O: need
for mechanical ventilation; T: study entry until 72 h of life.
Statistical analysis
The primary efficacy analysis will be conducted on an
intention-to-treat basis. An as-treated analysis will also
be implemented for secondary analyses if a large number
of infants do not end up getting the treatment to which
they were assigned. Clinical characteristics of infants in
the “IN-REC-SUR-E” and “IN-SUR-E” groups will be de-
scribed using mean values and standard deviation, me-
dian value and range, or rate and percentage. Univariate
statistical analysis will be performed using the Student’s
t test for parametric continuous variables, the Wilcoxon
rank-sum test for non-parametric continuous variables,
and Fisher’s exact test for categorical variables. A p value
<0.05 will be considered statistically significant. Then,
treatment arm and clinical characteristics which are
most likely associated with the need for mechanical
ventilation (gestational age, birth weight, antenatal
steroids, CRIB score) will be included in a multiple
logistic regression analysis to assess their independent
role in predicting the clinical outcome. Effect esti-
mates will be expressed as odds ratios (ORs) with
maximum likelihood-based 95 % confidence limits.
An interim analysis will be planned when 50 infants
will be enrolled in each arm. The analysis will intend
to compare treatment arms with respect to efficacy,
safety, futility, assessment of difficulties with patient
enrollment, and, if necessary, a sample size adjust-
ment. In the interim analysis for safety the pre-
specified stopping rules are: a mortality rate more
than 40 %, a rate of severe IVH more than 30 % and
a pneumothorax rate of more than 10 %. The
interim-analysis will be performed by an independent
statistician, blinded for the treatment allocation. The
statistician will report to the independent Data and
Safety Monitoring Board (DSMB). The DSMB will
have unblinded access to all data and will discuss the
results of the interim-analysis with the Steering Com-
mittee in a joint meeting. The Steering Committee
will decide on the continuation of the trial and will
report to the central Ethics Committee.
Duration of study
In this study, 206 infants will be recruited. The trial will
terminate when the last recruited infant is discharged
from hospital, or dies.
Quality control and quality assurance procedures
Compliance to protocol
Compliance will be defined as full adherence to protocol.
Compliance with the protocol will be ensured by a num-
ber of procedures as described below.
Site set-up
Local principal investigators are required to participate
in preparatory meetings in which details of study proto-
col, data collection, “IN-REC-SUR-E” and “IN-SUR-E”
procedures will be accurately discussed. All centers will
receive detailed written instruction on web-based data
recording, and, to solve possible difficulties, it will be
possible to contact the Clinical Trials Coordinating Cen-
ter (Policlinico A. Gemelli, Rome). Moreover, it has been
ascertained that the “IN-REC-SUR-E” procedure is
followed similarly in all participating centers.
Data processing and monitoring
All study data will be:
1) Screened for out-of-range data, with cross-checks
made for conflicting data within and between data
collection forms by a data manager
2) Referred back to the relevant center for clarification
in the event of missing items or uncertainty. A
record of all discrepancies and resolutions will be
kept by the data manger
The chief investigator and trial statistician will review
the results generated for logic and for patterns or prob-
lems. Outlier data will be investigated.
Safety
Safety end-point measures will include incidence, sever-
ity, and causality of reported serious adverse events
(SAEs), namely changes in the occurrence of the ex-
pected common prematurity complications and clinical
laboratory test assessments, and the development of un-
expected SAEs in this high-risk population. All SAEs will
be followed until satisfactory resolution is achieved or
until the investigator responsible for the care of the par-
ticipant deems the event to be chronic or the patient to
be stable. All expected and unexpected SAEs, whether
or not they are attributable to the study intervention,
will be reviewed by the local principal investigators to
Vento et al. Trials  (2016) 17:414 Page 6 of 10
determine if there is a reasonable suspected causal
relationship to the intervention. If the relationship is
reasonable, SAEs will be reported to chief investigators
who will report to the Ethics Committee and request all
investigators to guaranty the safety of all participants.
Dissemination policy
The scientific integrity of the project requires that the
data from all sites be analyzed study-wide and reported
as such. All presentations and publications are expected
to protect the integrity of the major objectives of the
study; data that break the blind will not be presented
prior to the release of mainline results. Recommenda-
tions as to the timing of presentation of such endpoint
data and the meetings at which they might be presented
will be given by the Steering Committee. Substantive
contributions to the design, conduct, interpretation, and
reporting of the clinical trial will be recognized through
the granting of authorship on the final trial report. Indi-
viduals who fulfill authorship criteria will have final au-
thority over the manuscript content.
Discussion
Lung aeration and FRC achievement represents a key
process for the fetal transition to newborn life. It
depends on the spontaneous inspiratory efforts, which
create transpulmonary pressure gradients [27], but also
on subsequent recruitment maneuvers in newborns with
RDS. Although surfactant replacement therapy is an
established treatment in infant RDS, the optimum
strategy for ventilatory management before, during, and
after surfactant instillation remains to be elucidated. It is
plausible to expect that the therapeutic benefits of ex-
ogenous surfactant therapy will be maximized by quickly
and uniformly aerating the lung beforehand. Ingimars-
son et al. examined whether a lung recruitment maneu-
ver just before surfactant would affect the response to
rescue treatment in immature lambs with established
RDS [28]. Five pairs of preterm twin lambs with a gesta-
tional age of 127 days were delivered by cesarean section
and supported by pressure-limited mechanical ventila-
tion for 4 h. At 30 min of age, when all the lambs were
in severe respiratory failure, they were treated with por-
cine surfactant, 200 mg/kg. One lamb in each pair was
subjected to a lung recruitment maneuver consisting of
five sustained inflations of 20 ml/kg just before surfac-
tant instillation. At 10 min after surfactant treatment, all
the lambs showed a large improvement in oxygenation
and an increase in inspiratory capacity and static compli-
ance. Except for a transiently better oxygenation after
surfactant therapy in the recruitment group (P <0.05),
there were no significant between-group differences in
gas exchange or lung mechanics at any time point dur-
ing the study. There was no difference in post-mortem
intrapulmonary air volume or alveolar expansion in histo-
logic lung sections between groups. This small study does
not show any positive or negative effect of a lung recruit-
ment maneuver on the response to rescue surfactant
therapy in immature animals with RDS. To explore the
impact of different surfactant doses and ventilation strat-
egies on the efficacy of surfactant treatment and ventilator
pressures in surfactant-depleted newborn piglets, van
Kaam et al. found that the efficacy of surfactant treatment
is less dose-dependent during open lung ventilation com-
pared with conventional positive pressure ventilation [29].
Moreover, open lung ventilation preserves the response to
delayed surfactant treatment in surfactant-deficient new-
born piglets, in contrast to conventional ventilation. This
sustained response is accompanied by an attenuation of
secondary lung injury [30]. More recently Tingay et al.
[31] described the interrelationship between antenatal ste-
roids, exogenous surfactant, and two approaches to lung
recruitment at birth on oxygenation and respiratory sys-
tem compliance in preterm lambs. They found that the ef-
fectiveness of surfactant maybe enhanced using PEEP-
based time-dependent recruitment strategies rather than
approaches solely aimed at initial lung liquid clearance. In
our previous randomized clinical trial comparing early
HFOV versus SIMV, the babies in the HFOV arm receiving
surfactant after a recruitment maneuver showed signifi-
cantly higher values of dynamic respiratory compliance
with respect to the SIMV-treated babies receiving surfac-
tant without a recruitment maneuver [32]. Our hypothesis
was that the atelectatic lung units were more adequately
opened by an optimal volume HFOV strategy than by
SIMV, suggesting there to be a recruitment of new alveolar
units rather than stabilization and distension of small
airways and alveolar spaces alone. From all the available
data, no definitive evidence exists about a positive effect of
recruitment before surfactant instillation, but a ration-
ale exists for testing the following hypothesis: a lung
recruitment maneuver performed with a step-by-step
CDP increase during HFOV (and not with a sustained
inflation) could have a positive effect in terms of
improved surfactant distribution and consequently
have major efficacy in preterm newborns with RDS.
This represents our challenge.
There are some limitations in our study design: (1)
surfactant replacement therapy involves instillation of a
liquid-surfactant mixture directly into the lung airway
tree. Thus, surfactant distribution and efficacy are not
only affected by lung recruitment before its administra-
tion but also depend on the methodology used for
delivery of the drug and on the post-administration
ventilatory management (prevention of collapse due to
inadequate weaning). In our study, different methods of
surfactant delivery will be used between the two groups.
In the group of infants submitted to a lung recruitment
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maneuver, surfactant will be delivered into the airways
without disconnection from the high frequency ventila-
tor. The control group will receive surfactant while
manually ventilated. On the other hand we cannot re-
cruit and stabilize the lung if we start positive pressure
ventilation in the IN-REC-SUR-E group, just to recruit
at the time of administration of surfactant and delivery
of positive pressure ventilation before/after its use. Re-
cruitment is a conceptual design usually applied from
start to finish. The fact that during IN-SUR-E we con-
ventionally ventilate the baby and during HFOV we do
not is inherent to the design of the study. If we would
‘bag’ the baby, recruitment will be lost and we will lose
the contrast between the groups (administer surfactant
in recruited or non-recruited lung). It is more an “open
lung ventilation” that is tested against conventional posi-
tive pressure ventilation. Open lung ventilation includes
surfactant administration in a recruited lung and avoid-
ing injury after administration. The difference in ventila-
tion during and after surfactant treatment is part of
optimal lung volume strategy. This makes our study
more of a “comparative effectiveness research” compar-
ing two distinct approaches that consist of several com-
ponents, rather than a simple randomized controlled
trial (RCT) comparing surfactant with and without a re-
cruitment maneuver; (2) failure of CPAP therapy is
multifactorial. Local experience with this therapy in the
smallest patients and type of CPAP applied seems to
play an important role in outcomes. Based on the results
of a recent survey on the neonatal respiratory support
strategies in the Italian NICUs [33], nCPAP is the most
commonly used non-invasive mode of respiratory sup-
port, both in the acute and post-extubation phases of
RDS. The most commonly used devices in delivering
non-invasive respiratory support are the Infant Flow®
System (56 %), mechanical ventilators (33 %), and bubble
CPAP (16 %). All the 37 NICUs involved in the present
study have considerable experience with non-invasive
respiratory support. Even though there could be poten-
tially different outcomes according to the different de-
vices used to deliver non-invasive respiratory support
pre and post extubation, this should not affect the differ-
ences between the two interventions in our study, be-
cause of the randomization; (3) some studies do show a
reduction in intubation need when N-IMV is used after
extubation. Even though there could be potentially dif-
ferent outcomes according to the different non-invasive
respiratory strategies used after extubation, it is conceiv-
able that clinicians will apply a specific non-invasive
ventilatory support (CPAP or BiPAP or N-IMV) similarly
in both groups. Although there might be differences
between centers, it will be similar within centers and be-
cause we randomize on center, this will not affect the
differences between the two groups.
Trial status
The trial is currently recruiting study subjects.
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The obstetricians are aware of the study protocol and will inform the
neonatologists of any case of high-risk preterm birth. Written and oral
information will, whenever possible, be offered to parents prior to birth
if the mother is at risk for preterm delivery and the infant is likely to be
eligible. In the few cases of spontaneous preterm labor and consequent
vaginal delivery, the informed consent will be obtained soon after the
birth. Informed written consent will be signed from both parents and
sufficient time will be provided for consent. If parents do not speak the
local language, consent will only be obtained if an adult and independent inter-
preter is available. The parents will be informed that the study does not entail a
blood sample or other more invasive interventions than maneuvers performed
regularly in the neonatal intensive care unit (NICU). The informed consent will
be obtained by the principal investigator of each participating center and his
collaborators in charge.
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